Rewalk Robotics Ltd
NASDAQ:LFWD

Watchlist Manager
Rewalk Robotics Ltd Logo
Rewalk Robotics Ltd
NASDAQ:LFWD
Watchlist
Price: 0.649 USD 1.72% Market Closed
Market Cap: 11.9m USD

Rewalk Robotics Ltd
Investor Relations

ReWalk Robotics Ltd. Is a medical device company, which engages in the design, development and marketing of wearable robotic exoskeletons. The firm is engaged in designing, developing and commercializing exoskeletons that allow individuals with mobility impairments or other medical conditions the ability to stand and walk once again. The firm offers ReWalk, which is an exoskeleton that uses its tilt-sensor technology and an on-board computer and motion sensors to drive motorized legs that power movement. ReWalk designs are intended for people with paraplegia, a spinal cord injury resulting in complete or incomplete paralysis of the legs, having the use of their upper bodies and arms. The firm offers two ReWalk products: ReWalk Personal and ReWalk Rehabilitation. ReWalk Personal is designed for everyday use by paraplegic individuals at home and in their communities, and is custom fitted for each user. ReWalk Rehabilitation is designed for use by paraplegia patients in the clinical rehabilitation environment, where it provides exercise and therapy.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 14, 2025
AI Summary
Q3 2025

Revenue Growth: Q3 revenue increased to $6.2 million, up 8% sequentially and 1.1% year-over-year, driven mainly by higher Medicare unit sales in the U.S.

Record ReWalk Placements: Lifeward delivered a record number of ReWalk exoskeleton units to Medicare beneficiaries for the second consecutive quarter following CMS fee schedule establishment.

Efficiency Gains: Operational improvements led to a 16% reduction in quarterly cash burn and a 27% decline in non-GAAP operating loss over last year.

Margin Expansion: Gross profit margin rose to 43.7% from 36.2% last year due to cost reductions after closing the Fremont, CA facility.

Liquidity Boost: Lifeward secured a $3 million loan after quarter-end, enhancing near-term liquidity.

Guidance Reaffirmed: Full-year 2025 revenue guidance of $24–26 million and non-GAAP net loss of $12–14 million was reaffirmed.

Global Expansion: CE Mark approval has expanded Lifeward’s European opportunity, with Germany showing strong pipeline momentum.

Key Financials
Revenue
$6.2 million
Gross Profit
$2.7 million
Gross Margin
43.7%
Operating Expenses
$5.9 million
Operating Loss
$3.1 million
Cash and Cash Equivalents
$2 million
Operating Cash Usage
$3.8 million
ReWalk Units Delivered
15 units
Traditional Products and Services Revenue
$3.1 million
DG Products and Services Revenue
$3.1 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Lawrence J. Jasinski BS, MBA
CEO & Director
No Bio Available
Mr. Michael A. Lawless
Chief Financial Officer
No Bio Available
Ms. Miri Pariente
Vice President of Operations, Regulatory & Quality
No Bio Available
Mr. Almog Adar
VP of Finance & Chief Accounting Officer
No Bio Available
Ms. Jeannine Lynch
Vice President of Market Access & Strategy
No Bio Available
Ms. Kathleen O'Donnell
Vice President of Marketing & New Business Development
No Bio Available
Ms. Judy Kula
Vice President of Customer Service, Human Resources & Business Affairs
No Bio Available

Contacts

Address
Yokneam
3 Hatnufa st. 6th fl., P.O. Box 161
Contacts
+97249590123.0
rewalk.com